Rosetta Genomics (ROSG) Reports Q4 Loss Per Share of $0.14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- Nasdaq futures underpinned by strong AI forecasts; focus on earnings, data
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Aegis Capital Still Positive on Rosetta Genomics (ROSG) Following Q4 Results; Nudges Ests Higher
March 24, 2016 11:41 AM EDTAegis Capital affirms Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $3.50 price target after ROSG reported Q4/FY15 results earlier Thursday.
Analyst Robert LeBoyer commented, We believe this quarterly report confirms our belief that the company has high-value cancer diagnostic... More
Rosetta Genomics (ROSG) Files $75M Mixed Shelf
March 23, 2016 4:48 PM EDTRosetta Genomics (NASDAQ: ROSG) filed a registration with the U.S. SEC to sell, from time to time, up to $75 million worth of mixed securities.
... More